Enrollment and Prescription Form Available Soon

The Enrollment and Prescription Form is not yet available.

Please check back to download the latest form.

Return to home

Return to previous page

REDUCTION IN PVR

OPSYNVI® Provided Greater Reductions in PVR Compared With Macitentan and Tadalafil Alone¹

Change in PVR at Week 16
(OPSYNVI® vs macitentan)¹

Change in PVR at Week 16
(OPSYNVI® vs tadalafil)¹

Treatment with OPSYNVI® (macitentan/tadalafil) resulted in a statistically significant treatment effect in PVR vs macitentan monotherapy and tadalafil monotherapy¹

Safety and Tolerability

Request a Medical
Science Liaison (MSL)Contact your MSL

CL=confidence limits; PAH=pulmonary arterial hypertension; PVR=pulmonary vascular resistance.

Reference: 1. OPSYNVI^® (macitentan/tadalafil) full Prescribing Information. Actelion Pharmaceuticals US, Inc.

To report suspected adverse reactions, contact Johnson & Johnson at 1-800-526-7736,
or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Contact Medical Information >

Cookie Policy

No footer links content fetched

OPSYNVI® Provided Greater Reductions in PVR Compared With Macitentan and Tadalafil Alone1

OPSYNVI® Provided Greater Reductions in PVR Compared With Macitentan and Tadalafil Alone¹